Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.67 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301510 | 0.98 | CYP4F2 (0.65) | CYP4F2CYP4A11FOLH1DHODHCYP2D6 | |
| SCHEMBL5473039 | 0.95 | CYP4F2 (0.62) | CYP4F2CYP4A11FOLH1DHODHCYP2D6 | |
| SCHEMBL16559877 | 0.89 | FOLH1 (0.66) | CYP4F2CYP4A11FOLH1CYP2D6CYP2C9 | |
| SCHEMBL334419 | 0.87 | CYP4F2 (0.64) | CYP4F2CYP4A11FOLH1DHODHCYP2D6 | |
| Isophthalic Acid SCHEMBL28054106 | 0.86 | NPC1 (0.53) | CYP4F2CYP4A11FOLH1KMT2A | |
| SCHEMBL1980273 | 0.85 | FOLH1 (0.61) | FOLH1CYP2D6CYP2C9HIF1AKMT2A | |
| Hydrochloric Acid SCHEMBL11527299 | 0.85 | CYP4F2 (0.62) | CYP4F2CYP4A11FOLH1DHODHCYP2D6 | |
| SCHEMBL371526 | 0.85 | FOLH1 (0.70) | FOLH1CYP2D6CYP2C9HIF1AANPEP | |
| Isophthalic Acid SCHEMBL4651781 | 0.85 | CA12 (0.56) | FOLH1CYP2C9ANPEPENPEP | |
| SCHEMBL443913 | 0.84 | RARB (0.58) | FOLH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | CYP4F2 564/4885CYP4A11 1158/4885FOLH1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.